IL-CULLIGAN
Culligan International (“Culligan”), the innovative brand in consumer-focused, sustainable water solutions and services, and Waterlogic Group Holdings (“Waterlogic”), a global designer, manufacturer, distributor and service provider of purified drinking water dispensers, announced today the completion of their transaction to combine, creating a leader in clean and sustainable drinking water solutions and services. Headquartered in Rosemont, Illinois, the combined company operates under the Culligan name.
With over 11,000 employees operating directly in 30 countries, Culligan generates combined annual revenues of about $2.4 billion and is well-positioned to expand in the fast-growing $35 billion global consumer water market. The combination diversifies the company’s product range and increases its global reach, including an expansive dealer network in more than 70 countries. It brings additional scale and expertise to drive innovation in the development of new household and commercial water filtration, purification and treatment solutions, expanding those to both existing and new markets, and it bolsters distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific.
“Our two organizations make a powerful combined team as one Culligan, aligned on values and committed to a clear purpose to change people’s lives and to improve the environment,” said Scott Clawson, President and CEO of Culligan International. “Culligan is a leading global consumer water solutions and services provider whose mission is to deliver clean, safe and soft water to improve consumers’ health and wellness and reduce single-use plastics. Serving over 100 million people globally, our solutions save more than 40 billion plastic bottles annually.”
“Our deep, mutual belief that we have the ability and responsibility to contribute positively to the Earth guides our decisions and is engrained in our operations,” said Jeremy Ben-David, founder and former Group CEO of Waterlogic who now serves Culligan as CEO of the Europe, Middle East and Africa region, and a member of the Executive Leadership of Culligan Global. “We take to heart the United Nations Sustainable Development Goals, and today we are aligned to make an even more positive impact in all we do.”
The combined company is majority owned by funds affiliated with BDT Capital Partners, LLC (“BDT”) and by the firm’s co-investors. In 2021, funds managed by BDT, an affiliate of BDT & Company, LLC, a merchant bank that works with family- and founder-led businesses to pursue their strategic and financial objectives, acquired Culligan alongside a group of strategic family business owners and investors within the firm’s global network. Waterlogic was acquired in January 2015 by funds managed by Castik Capital, a European private equity investor, which alongside former Waterlogic management team members and other shareholders, has a meaningful minority ownership position in Culligan.
Terms of the transaction were not disclosed.
About Culligan International
Founded in 1936 and headquartered in Rosemont, Illinois, Culligan International makes a real difference to people’s lives by providing clean, safe, great-tasting water to more than 100 million consumers globally. With over 11,000 employees in 30 countries, we generate combined annual revenues of about $2.4 billion and are well-positioned to expand in the $35 billion global consumer water market. Culligan is one of the world’s most-recognized and trusted names in water, a reputation built through an 85-year legacy of trust, innovation, service and quality. The Culligan master brand covers a family of iconic brands and innovative technologies that include Quench, Blupura, Zip Water, Purezza Premium Water and Firewall® UVC purification. Our combination with Waterlogic diversifies our product range and increases our global reach, including through an expansive dealer network in over 70 countries. It helps bring a breadth of household, commercial and retail solutions to new markets and distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific. As a purpose-led business, we strive to reduce the environmental impact across the supply chain, and we save more than 40 billion plastic bottles annually through our sustainable water filtration, purification and treatment solutions. For more information visit: www.corporate.culligan.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
